Long Rou, Zuo Hanrong, Tang Guiyang, Zhang Chaohui, Yue Xinru, Yang Jinsai, Luo Xinyu, Deng Yuqi, Qiu Jieya, Li Jiale, Zuo Jianhong
Institute of Translational Medicine, School of Basic Medical, Department of Special Medicine, Hengyang Medical College, University of South China, Hengyang, Hunan, China.
Hunan University of Chinese Medicine, Department of Clinical Medicine, Changsha, Hunan, China.
Front Immunol. 2025 May 21;16:1516419. doi: 10.3389/fimmu.2025.1516419. eCollection 2025.
Antibody-Drug Conjugates (ADCs) represent an emerging cancer therapeutic strategy and are becoming increasingly significant in the field of public health. With the evolution of precision oncology, the potential applications of ADCs are being realized more broadly. This review provides an overview of the fundamental molecular design of ADCs, examining how each component-antibody, linker, payload, and coupling chemistry-affects the physicochemical and biological properties of the final product. The paper also discusses novel ADC designs that are in preclinical and early clinical development stages as next-generation cancer therapies. These include bispecific ADCs, Probody-drug conjugate, immunostimulatory ADCs (ISACs), Degrader-Antibody Conjugates (DACs), and Dual-Payload ADCs. Their applications and potential future advancements in cancer therapy are also explored.
抗体药物偶联物（ADCs）是一种新兴的癌症治疗策略，在公共卫生领域正变得越来越重要。随着精准肿瘤学的发展，ADCs的潜在应用正在更广泛地得到实现。本综述概述了ADCs的基本分子设计，研究了每个组件——抗体、连接子、有效载荷和偶联化学——如何影响最终产品的物理化学和生物学特性。本文还讨论了作为下一代癌症疗法正处于临床前和早期临床开发阶段的新型ADCs设计。这些包括双特异性ADCs、前体药物偶联物、免疫刺激ADCs（ISACs）、降解剂-抗体偶联物（DACs）和双有效载荷ADCs。还探讨了它们在癌症治疗中的应用以及未来可能的进展。
